On May 14, 2020, Abbott’s ID NOW announced that was further clarifying product information to provide better guidance to healthcare providers that negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

Negative results should be presumed negative, but if inconsistent with clinical signs and symptoms or necessary for patient management, should be tested with an alternative molecular assay.